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SHORT COMMUNICATION
Feasibility of Dried Blood Spots in Children with Behavioral
Problems
Sanne M. Kloosterboer, MD,*† Estelle van Eijk, BSc,* Monique van Dijk, PhD,‡
Gwen C. Dieleman, MD, PhD,† Manon H. J. Hillegers, MD, PhD,† Teun van Gelder, MD, PhD,*
Birgit C. Koch, PharmD, PhD,* and Bram Dierckx, MD, PhD†
Background: Minimally invasive sampling methods are important
to facilitate therapeutic drug monitoring and pharmacokinetic
research in children with behavioral problems. This study assessed
the feasibility and pain of dried blood spot (DBS) sampling in this
population.
Methods: Repeated DBS sampling was performed in children with
autism spectrum disorder (ASD) and severe behavioral problems
using antipsychotic drugs, aged between 6 and 18 years. The child,
guardian, and DBS performer assessed pain using the numeric rating
scale (NRS-11) or 5-face Faces Pain Scale. The influence of age, sex,
and the fingerprick performer on the child’s pain intensity was ana-
lyzed using linear mixed models.
Results: Overall, 247 fingerpricks were performed in 70 children.
Seven children refused all DBS sampling. The median (interquartile
range) NRS-11 pain scores were 2 (3) rated by children, 3 (2.5) by
guardians, and 2 (2) by fingerprick performers. The child’s age and
sex, and fingerprick performer had no significant influence on pain
intensity.
Conclusions: DBS sampling could be performed in most children
with ASD and severe behavioral problems. However, 1 in 5 children
refused one or more DBS fingerpricks owing to distress. Most
expressed minimal pain (NRS , 4). Repeated sampling with DBS is
feasible in children with ASD and severe behavioral problems.
Key Words: dried blood spot, children, adolescents, autism spec-
trum disorder, behavioral problems
(Ther Drug Monit 2020;42:648–651)
INTRODUCTION
As an alternative to invasive venipuncture, dried blood
spot (DBS) analysis is well established for drug quantification.1
DBS involves only one fingerprick and is especially suited for
pediatric populations, in clinical and research settings. DBS
can increase sampling tolerability particularly in children with
behavioral problems. In these children, blood sampling by
venipuncture is often challenging due to restlessness or aggres-
sion; the minimally invasive DBS procedure could overcome
these challenges and can be performed at home.
Notably, among children with behavioral problems, DBS
sampling is of particular interest in children prescribed antipsy-
chotic drugs. These drugs are effective in a wide range of
psychiatric disorders in childhood,2 including behavioral prob-
lems in autism spectrum disorder (ASD); however, these drugs
are associated with serious side effects. The most important side
effect concerns weight gain,3 leading to metabolic abnormali-
ties,3 diabetes mellitus,4 cardiovascular diseases,5 and possibly
even unexpected death6 in children using antipsychotic drugs.
Therapeutic drug monitoring (TDM) could be an important tool
to increase the safety of these drugs in children.7,8
To facilitate TDM research and applicability in children
using antipsychotic drugs, a DBS assay for the quantification
of risperidone, aripiprazole, and pipamperone has been
developed.9,10 However, the feasibility and burden of DBS
in children with severe behavioral problems remains unex-
plored. In this study, we evaluated the feasibility and pain
levels of DBS sampling in children with ASD and severe
behavioral problems and investigated the influence of sex,
age, and fingerprick performer on the child’s pain intensity.
MATERIALS AND METHODS
Study Population
Children, aged 6–18 years, with ASD according to the
Diagnostic and Statistical Manual of Mental Disorders IV11
or 512 and severe behavioral problems were included in an
observational study investigating the relationship between
antipsychotic drug concentrations and effects (the
Netherlands National Trial Register NTR6050). All included
children were prescribed risperidone, aripiprazole, or pipam-
perone, the 3 most commonly used antipsychotic drugs in the
Netherlands.13 This study, including the pain assessments,
was approved by the medical ethics committee of the
Erasmus MC (MEC 2016-124). All patients and/or their legal
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representatives provided written informed consent before
entering the study.
DBS Sampling
Each child received 2 to 3 fingerpricks on 2 separate
days, with a minimum of 1 hour between 2 fingerpricks to
allow random sampling. The fingerpricks were performed
with a single-use contact-activated lancet (BD Microtainer 2.0
· 1.5 mm), with the first performed by the research staff at the
clinic. Subsequent fingerpricks were performed by research
staff, the guardian, or the child itself, at the clinic or home
depending on the patient’s preference. Most children under-
went a venipuncture the same day. Antipsychotic drug con-
centrations were determined using a previously validated
ultra-high performance liquid chromatography-mass spec-
trometry method for DBS9,10
Pain Assessment
Before performing the fingerprick, the child’s likely
response to procedures, coping strategies, and possible inter-
ventions were discussed with parents and the child. The DBS
procedure was explained and demonstrated before the perfor-
mance. Immediately after the fingerprick, the child, guardian,
and fingerprick performer assessed pain. Children aged 6
years used a 5-face Faces Pain Scale; older children, guard-
ians, and fingerprick performers used the 11-point numeric
rating scale (NRS-11).14 The Faces Pain Scale demonstrates 5
faces from happy to extremely sad. For children with cogni-
tive impairment, the Checklist Pain Behavior (CPG),15
including the NRS-11, was scored by the research staff,
whereas the guardians only scored the NRS-11. An NRS
score of 4 or higher and a CPG score of 5 or higher is re-
garded as an indication for pain-relieving interventions.15,16
After each fingerprick, the researcher evaluated the burden for
each child based on pain scores, assessing whether a subse-
quent fingerprick could be performed together with the child
and the guardian.
Statistical Analyses
Groups were compared using the Mann–Whitney U
test for continuous data (nonnormal data distribution) and
the Fisher exact test for categorical data. The interrater
reliability of pain scores rated by the child, guardian, and
research staff was analyzed with the intraclass correlation
coefficient using a 2-way mixed model with absolute
agreement type. To evaluate the influence of the child’s age
and sex, as well as fingerprick performer, on the child’s pain,
a linear mixed model analysis was used with a random
intercept. Sampling days were clustered within patients. All
variables were tested using a univariate model. Variables
with P , 0.10 were added to the multivariate model; vari-
ables with P , 0.05 in this model were selected for the final
model. All analyses were performed using SPSS version 25
(SPSS Inc, Chicago, IL).
RESULTS
Overall, 81 children were eligible for inclusion. Seven
children refused all DBS sampling (8.6%), and in 9 children
(11.1%) not all DBS sampling could be performed as they
expected DBS to be extremely painful or stressful (Fig. 1).
Children who refused one or more DBS samples were signif-
icantly younger than those who performed all DBS samples
(median age 9.3 versus 10.8 years, P = 0.43). The groups did
not significantly differ in terms of sex or mental retardation.
Totally, 253 DBS samples were collected from 70
children, with 21 female (30%) children, and a median
[interquartile range (IQR)] age of 10.7 (5.0) years. Twelve
children were diagnosed with cognitive impairment. Most
DBS fingerpricks were performed by research staff (63.0%),
followed by guardians (36.6%) and the child (0.4%). DBS
samples obtained by guardians were performed at home.
Notably, 39 (15.4%) DBS samples were not of sufficient
quality for analysis.
For 247 DBS samples, 1 or more NRS-11 pain scores
were available, including 168 pain scores reported by the
child, 187 by guardians, and 126 by research staff. The
median (IQR) NRS-11 pain scores were 2 (3) rated by
children, 3 (2.5) by guardians, and 2 (2) by research staff. The
medians and ranges are shown in Figure 2. Furthermore, 61
fingerpricks (36.3%) were rated $4 by the child. Twenty-six
CPG scores were available; the median (IQR) score was 3 (1)
and 11.5% were 5 or higher.
For 147 fingerpricks, both child and guardian NRS-11
pain scores were available. The intraclass correlation coeffi-
cient for guardians and children was 0.86 (95% CI 0.81–0.90)
and for research staff and children was 0.79 (95% CI 0.67–
0.86), considered excellent and good, respectively.
For 167 NRS-11 scores issued by the child, the age
and sex of the child, as well as the nature of fingerprick
performer, were known. The univariate mixed model
analysis showed that none of these variables significantly
influenced the child’s pain intensity as follows: age of the
child (b = 20.087, P = 0.134), sex of the child (b = 0.476,
P = 0.225), and fingerpick performer (guardian b = 0.266,
P = 0.211, self b = 1.178, P = 0.548, with research staff as
reference category).
DISCUSSION
Repeated DBS sampling was successfully performed in
most children with ASD and severe behavioral problems.
Nevertheless, 1 in 5 children refused one or more DBS
fingerpricks due to distress. However, most children ex-
pressed minimal pain (NRS , 4) during DBS sampling.
Relatively little is known regarding pain in autistic
children, although hyperreactivity or hyporeactivity to sen-
sory input is a feature of ASD.12 Comparable, reduced, and
increased pain thresholds have been reported in the litera-
ture.17 This is consistent with our study, where both
extremely low and extremely high pain scores were observed,
although most pain scores were lower than the generally
accepted threshold of 4. However, pain assessment in chil-
dren with ASD is challenging because they may express pain
differently due to the lack of social responsiveness and lan-
guage impairment.18 Unfortunately, pain assessment tools
specifically for individuals with ASD have remained largely
unexplored.
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The tolerability of blood sampling is not only deter-
mined by pain but also by distress and anxiety. Children with
ASD express higher levels of distress during venipuncture
than their nonimpaired peers.19,20 DBS sampling may reduce
many of these stressors because the sampling preparation
phase is considerably less complex, allowing sampling by
a guardian in the home setting. Hence, most children with
high levels of distress are expected to prefer DBS sampling
over venipuncture, as do their normally developing peers,21,22
but further research is necessary for validation.
In children with behavioral problems, the performance of
repeated sampling studies is highly challenging. As previously
suggested, sparse sampling designs in combination with DBS
sampling can facilitate pediatric pharmacokinetic research.23,24
Both the lower burden and acceptance of home sampling
improve study recruitment, which is particularly difficult in
child and adolescent psychiatry. However, clinical validation
remains challenging, for example, our study showed a larger
variability in antipsychotic drug concentrations measured with
DBS than with venipuncture. As advanced pharmacokinetic
modeling techniques allow the correction of this variability,
the advantages of DBS can still outweigh the disadvantages.
Currently, this method remains primarily useful in research
settings; however, further development and study of DBS
and TDM could yield a clinical, minimally invasive tool that
improves the safety of antipsychotic drugs.
This study has some limitations. As mentioned earlier,
self-reporting of pain might be unreliable in children with ASD,
leading to an overestimation or underestimation of pain.
However, no pain measurement tools are currently available
for pain assessment specifically in children with ASD. To
optimize pain assessment, it was ensured that the DBS sampling
performers had previous experience in communicating with
children with ASD and that the child’s guardians were present.
Previous research has shown that parent involvement is essential
for the interpretation and expression of pain in children with
ASD.18 A comparison with the pain associated with conven-
tional venipuncture was not conducted, limiting the evaluation
of the most optimal sampling technique in this population.
Figure 1. DBS sampling fulfillment.
FIGURE 2. Child’s pain associated with DBS sampling rated by
child, guardian, and research staff. Whiskers indicate
minimum–maximum. .
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CONCLUSIONS
This is the first study that evaluated the feasibility of
repeated DBS sampling in children with ASD and severe
behavioral problems, indicating that DBS is a feasible
sampling technique in this population. Although further
research is needed to compare the burden of DBS and
venipuncture in children with ASD and behavioral problems,
DBS can facilitate pharmacokinetic research and TDM in
these and other pediatric populations where sampling remains
challenging.
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